title: Update on Therapeutic Options for Helicobacter pylori-related Diseases.
abstract: Triple therapy including clarithromycin, amoxicillin, and a proton pump inhibitor (PPI) has been recommended as the treatment of choice for Helicobacter pylori eradication. This regimen is now challenged by an increasing level of clarithromycin resistance that jeopardizes the treatment success. When clarithromycin resistance has been detected, or when its rate is known to be high in the geographic area, this drug cannot be used. It can be replaced by metronidazole, the resistance of which has a limited clinical relevance. Another option is to prescribe tetracycline and metronidazole with a PPI or ranitidine bismuth citrate. New antibiotics such as levofloxacin or rifabutin can also be used in combination with amoxicillin and a PPI. Probiotics can be added to all of these regimens to improve compliance by decreasing adverse events. But some authors advocate a quadruple therapy as a first-line treatment. Solutions to improve the limitations of this last regimen are now being proposed. Clarification of the controversial treatment indications such as gastroesophageal reflux disease or prevention of nonsteroidal anti-inflammatory drug gastroduodenal symptoms has been made. The question of prevention of gastric carcinoma by H. pylori eradication remains unanswered.
authors.affiliation: Laboratoire de Bactériologie, Hôpital Pellegrin, 33076 Bordeaux Cedex, France. francis.megraud@chu-bordeaux.fr.
authors.forename: Francis
authors.initials: F
authors.lastname: Mégraud
references.citation: Gastroenterol Clin Biol. 2002 Mar;26(3):216-9
references.pmid: 11981460
references.citation: Dig Liver Dis. 2004 Jun;36(6):384-7
references.pmid: 15248377
references.citation: World J Gastroenterol. 2004 Jun 1;10(11):1656-8
references.pmid: 15162544
references.citation: Am J Gastroenterol. 2004 Sep;99(9):1833-55
references.pmid: 15330927
references.citation: Aliment Pharmacol Ther. 2003 Sep 15;18(6):647-54
references.pmid: 12969092
references.citation: Aliment Pharmacol Ther. 2000 May;14(5):603-9
references.pmid: 10792124
references.citation: Aliment Pharmacol Ther. 2004 Feb 1;19(3):253-61
references.pmid: 14984371
references.citation: Clin Gastroenterol Hepatol. 2004 Nov;2(11):997-1002
references.pmid: 15551252
references.citation: Aliment Pharmacol Ther. 2003 Jan;17(1):99-109
references.pmid: 12492738
references.citation: J Gastroenterol Hepatol. 2003 Jul;18(7):778-82
references.pmid: 12795748
references.citation: Can J Gastroenterol. 2003 Jun;17 Suppl B:36B-40B
references.pmid: 12845349
references.citation: Aliment Pharmacol Ther. 2002 Apr;16(4):793-8
references.pmid: 11929398
references.citation: Gut. 2004 Sep;53(9):1374-84
references.pmid: 15306603
references.citation: JAMA. 2004 Jan 14;291(2):187-94
references.pmid: 14722144
references.citation: J Clin Microbiol. 2003 Jan;41(1):397-402
references.pmid: 12517879
references.citation: Aliment Pharmacol Ther. 2004 Nov 15;20(10):1071-82
references.pmid: 15569109
references.citation: J Antimicrob Chemother. 2001 May;47(5):709-10
references.pmid: 11328791
references.citation: Aliment Pharmacol Ther. 2003 Oct 15;18(8):791-7
references.pmid: 14535872
references.citation: Can J Gastroenterol. 1999 Apr;13(3):213-7
references.pmid: 10331931
references.citation: Aliment Pharmacol Ther. 2003 Jun 15;17(12):1545-51
references.pmid: 12823158
references.citation: Aliment Pharmacol Ther. 2000 Dec;14(12):1639-43
references.pmid: 11121913
references.citation: Aliment Pharmacol Ther. 2004 Nov 15;20(10):1181-8
references.pmid: 15569121
references.citation: J Gastroenterol. 2004 Nov;39(11):1051-5
references.pmid: 15580397
references.citation: Am J Gastroenterol. 2003 Mar;98(3):562-7
references.pmid: 12650788
references.citation: Aliment Pharmacol Ther. 2004 Feb;19 Suppl 1:9-16
references.pmid: 14725573
references.citation: Gut. 2004 Feb;53(2):312-3
references.pmid: 14724171
references.citation: Aliment Pharmacol Ther. 2002 Feb;16(2):167-80
references.pmid: 11860399
references.citation: Aliment Pharmacol Ther. 2003 Feb;17(3):415-20
references.pmid: 12562455
references.citation: Helicobacter. 1999 Jun;4(2):106-12
references.pmid: 10382124
references.citation: Am J Med. 2004 Sep 6;117 Suppl 5A:86S-91S
references.pmid: 15478858
references.citation: Aliment Pharmacol Ther. 2003 Jun 1;17(11):1333-43
references.pmid: 12786627
references.citation: Aliment Pharmacol Ther. 2000 Oct;14(10):1339-43
references.pmid: 11012480
references.citation: Am J Gastroenterol. 2000 Nov;95(11):3317-8
references.pmid: 11095372
references.citation: Aliment Pharmacol Ther. 2000 Mar;14(3):311-6
references.pmid: 10735924
references.citation: J Clin Gastroenterol. 2000 Oct;31(3):222-5
references.pmid: 11034001
references.citation: J Gastroenterol Hepatol. 1998 Jan;13(1):1-12
references.pmid: 9737564
references.citation: Lancet. 1984 Jun 16;1(8390):1311-5
references.pmid: 6145023
references.citation: Gut. 1997 Jul;41(1):8-13
references.pmid: 9274464
references.citation: Eur J Gastroenterol Hepatol. 2004 Oct;16(10):987-90
references.pmid: 15371921
references.citation: Am J Gastroenterol. 2000 Oct;95(10):2688-91
references.pmid: 11051336
references.citation: J Clin Microbiol. 2004 Oct;42(10):4512-8
references.pmid: 15472302
references.citation: Clin Gastroenterol Hepatol. 2003 Jul;1(4):273-8
references.pmid: 15017668
references.citation: Helicobacter. 2003 Apr;8(2):90-4
references.pmid: 12662375
references.citation: Aliment Pharmacol Ther. 2003 Oct 15;18(8):821-7
references.pmid: 14535876
references.citation: Helicobacter. 2004 Apr;9(2):124-9
references.pmid: 15068413
references.citation: J Antimicrob Chemother. 2000 Dec;46(6):1029-31
references.pmid: 11102427